glp-1 news 2025 november in review: breakthroughs, UPFs under fire, Novonesis advances healthy longevity Harvard Medical School Researcher Wins

GLP-1 medications decreased fatal stroke by 26% and non-fatal stroke by 13% 16

GLP-1 injections, also known as glucagon-like peptide-1 receptor agonists, are a treatment originally developed for managing type 2 diabetes

We need more support around our clinicians who are providing treatments, said Jamy Ard, MD, past president of The Obesity Society and co-director of Atrium Health Wake Forest Baptist Weight Management Center

Many responded, sharing their experiences honestly sometimes humorously, sometimes painfully often with the hope that being open might help someone else feel more informed or less alone

The aim of their project was to determine the degree to which infusions of GLP-1 (7-36) stimulated the release of insulin compared with synthetic versions of GIP

Simultaneously, these medications suppress glucagon secretion from pancreatic alpha cells, further contributing to improved glycemic control